Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HERNAN A SALAZAR

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1538220892
CMS profile
919244
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$713.29

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $359.25 3
Food and Beverage $354.04 20

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $671.70 21
Novartis Pharmaceuticals Corporation $41.59 2

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HERNAN A SALAZAR

NPI 1538220892 · CMS profile ID 919244

Allopathic & Osteopathic Physicians / Internal Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538220892?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $713.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $288.6009/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657865861 CMS
Eli Lilly and Company $4.6209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709007629 CMS
Eli Lilly and Company $33.2609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008115 CMS
Eli Lilly and Company $11.0909/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008833 CMS
Eli Lilly and Company $44.3409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008835 CMS
Eli Lilly and Company $25.8709/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008837 CMS
Eli Lilly and Company $3.3309/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709008839 CMS
Eli Lilly and Company $23.6409/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009169 CMS
Eli Lilly and Company $8.3209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009171 CMS
Eli Lilly and Company $10.9809/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009173 CMS
Eli Lilly and Company $18.4809/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009175 CMS
Eli Lilly and Company $4.4309/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009177 CMS
Eli Lilly and Company $8.2509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009343 CMS
Eli Lilly and Company $59.6709/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009345 CMS
Eli Lilly and Company $5.9109/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009347 CMS
Eli Lilly and Company $1.8509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009653 CMS
Eli Lilly and Company $2.0609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009655 CMS
Eli Lilly and Company $10.3509/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009833 CMS
Eli Lilly and Company $2.3609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709009835 CMS
Eli Lilly and Company $103.4709/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709010581 CMS
Eli Lilly and Company $0.8209/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709010583 CMS
Novartis Pharmaceuticals Corporation $20.5008/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660037539 CMS
Novartis Pharmaceuticals Corporation $21.0904/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660037537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $713.29 23
PY2020 $397.53 3
PY2023 $727.75 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $189,942.29 38
PY2024 Principal investigator $116,310.00 16
PY2023 Recipient $291.00 1
PY2023 Principal investigator $1,683,804.34 55
PY2022 Recipient $1,491.00 2
PY2022 Principal investigator $4,307,067.33 117
PY2021 Recipient $201.98 1
PY2021 Principal investigator $8,685,200.41 155
PY2020 Recipient $145.50 1
PY2020 Principal investigator $2,390,117.44 47
PY2019 Recipient $705.39 1
PY2019 Principal investigator $1,142,050.05 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $172,477.00 12/22/2023 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986098987
Principal investigator 1 Janssen Research & Development, LLC $74,830.00 11/01/2023 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986098983
Principal investigator 1 Endo Pharmaceuticals Inc. $1,000.00 10/11/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033264919
Principal investigator 1 Janssen Research & Development, LLC $5,930.00 09/26/2023 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986098977
Principal investigator 1 Endo Pharmaceuticals Inc. $1,613.00 08/23/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033261923
Principal investigator 1 Endo Pharmaceuticals Inc. $1,331.00 08/16/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033261461
Principal investigator 1 Endo Pharmaceuticals Inc. $10,306.00 07/19/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033260231
Principal investigator 1 Endo Pharmaceuticals Inc. $3,450.00 06/14/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033258181
Principal investigator 1 Janssen Research & Development, LLC $13,800.00 06/12/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 986148609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $225.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $296.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $35.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $340.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $246.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $750.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 06/09/2023 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 997041811
Principal investigator 1 Endo Pharmaceuticals Inc. $8,090.00 05/24/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033256959
Principal investigator 1 BioNTech SE $500.00 05/11/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Pre-commercial No dispute reported 06/30/2026 1060314917
Recipient Eli Lilly and Company $291.00 04/28/2023 Covered Recipient Physician A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 1038051547
Principal investigator 1 BioNTech SE $15,368.15 04/26/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Pre-commercial No dispute reported 06/30/2026 1060317315
Principal investigator 1 Endo Pharmaceuticals Inc. $8,812.00 04/26/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033254655
Principal investigator 1 Janssen Research & Development, LLC $17,710.00 04/21/2023 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986098971
Principal investigator 1 Endo Pharmaceuticals Inc. $2,578.00 04/12/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033254333
Principal investigator 1 Endo Pharmaceuticals Inc. $707.00 04/12/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033254345
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 03/31/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Study for the identification of subjects who are homozygous for the PNPLA3 I148M mutation and have Nonalcoholic fatty liver disease (NAFLD) No dispute reported 06/30/2026 986148673
Principal investigator 1 BioNTech SE $7,778.00 03/29/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Pre-commercial No dispute reported 06/30/2026 1060318055
Principal investigator 1 BioNTech SE $1,500.00 03/29/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Pre-commercial No dispute reported 06/30/2026 1060318057
Principal investigator 1 BioNTech SE $2,592.00 03/29/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Pre-commercial No dispute reported 06/30/2026 1060318061
Principal investigator 1 BioNTech SE $12,000.00 03/29/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Pre-commercial No dispute reported 06/30/2026 1060318063
Principal investigator 1 BioNTech SE $21,151.75 03/24/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Pre-commercial No dispute reported 06/30/2026 1060318069
Principal investigator 1 Janssen Research & Development, LLC $13,387.00 03/20/2023 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986098939
Principal investigator 1 Janssen Research & Development, LLC $10,953.00 03/17/2023 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986098941
Principal investigator 1 Endo Pharmaceuticals Inc. $11,339.00 03/15/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033253139
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $13,630.05 03/15/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
A Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of a Single Dose of VX-121/Tezacaftor/Deutivacaftor in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects No dispute reported 06/30/2026 1006170447
Principal investigator 1 AstraZeneca UK Limited $87,796.77 03/01/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Phase I, Parallel-group,Multi-center,Open-label Investigation of the Pharmacokinetics,Safety and Tolerability of a Single Subcutaneous Injection of Cotadutide in Participants with Mild,Moderate or Severe Hepatic Impairment Compared to Participants with Normal Hepatic Function No dispute reported 06/30/2026 991134965
Principal investigator 1 AstraZeneca UK Limited $11,878.04 02/27/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AZD2693, Cardiovascular, Renal and Metabolism No dispute reported 06/30/2026 991138311
Principal investigator 1 Eli Lilly and Company $171.00 02/23/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 1038094501
Principal investigator 1 Dexcom, Inc. $22,031.00 02/22/2023 Non-covered Recipient Entity
Endeavor Clinical Trials, LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (G7PIV#2) No dispute reported 06/30/2026 1060231627
Principal investigator 1 Janssen Research & Development, LLC $13,340.00 02/22/2023 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986098943
Principal investigator 1 Eli Lilly and Company $5,815.74 02/17/2023 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 1038090793
Principal investigator 1 Endo Pharmaceuticals Inc. $2,662.00 02/15/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033251357
Principal investigator 1 Endo Pharmaceuticals Inc. $8,431.00 02/15/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033251373
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $1,015,977.18 01/27/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty No dispute reported 06/30/2026 1006171383
Principal investigator 1 Janssen Research & Development, LLC $38,676.00 01/25/2023 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 986098945
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,108.65 01/25/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1017194545
Principal investigator 1 Endo Pharmaceuticals Inc. $5,862.00 01/18/2023 Non-covered Recipient Entity
ENDEAVOR CINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033249961
Principal investigator 1 Heron Therapeutics, Inc. $1,859.00 01/12/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A PHASE 4, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED STUDY OF HTX-011 IN SUBJECTS UNDERGOING DIFFERENT SURGICAL PROCEDURES No dispute reported 06/30/2026 1057177789
Principal investigator 1 Vertex Pharmaceuticals Incorporated $9,078.01 01/10/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
A Phase 2 Randomized Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty No dispute reported 06/30/2026 1006163895
Principal investigator 1 Endo Pharmaceuticals Inc. $4,161.00 01/04/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033248275
Principal investigator 1 Endo Pharmaceuticals Inc. $657.00 01/04/2023 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 1033248291
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 01/04/2023 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 1039730943